Stem definition | Drug id | CAS RN |
---|---|---|
analgesic anti-inflammatory | 880 | 22494-42-4 |
Dose | Unit | Route |
---|---|---|
0.75 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 6 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 99.92 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 85 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.10 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 0.10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.00 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 10 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
April 19, 1982 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug hypersensitivity | 41.70 | 31.19 | 26 | 412 | 310661 | 63177923 |
None
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Urine protein/creatinine ratio increased | 58.16 | 33.07 | 10 | 704 | 1224 | 79742450 |
Urinary occult blood positive | 34.33 | 33.07 | 5 | 709 | 210 | 79743464 |
None
Source | Code | Description |
---|---|---|
ATC | N02BA11 | NERVOUS SYSTEM ANALGESICS OTHER ANALGESICS AND ANTIPYRETICS Salicylic acid and derivatives |
FDA CS | M0001335 | Anti-Inflammatory Agents, Non-Steroidal |
FDA MoA | N0000000160 | Cyclooxygenase Inhibitors |
MeSH PA | D000700 | Analgesics |
MeSH PA | D018712 | Analgesics, Non-Narcotic |
MeSH PA | D000893 | Anti-Inflammatory Agents |
MeSH PA | D000894 | Anti-Inflammatory Agents, Non-Steroidal |
MeSH PA | D018501 | Antirheumatic Agents |
MeSH PA | D016861 | Cyclooxygenase Inhibitors |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D018689 | Sensory System Agents |
FDA EPC | N0000175722 | Nonsteroidal Anti-inflammatory Drug |
CHEBI has role | CHEBI:35475 | non-steroidal anti-inflammatory agent |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Pain | indication | 22253000 | |
Rheumatoid arthritis | indication | 69896004 | DOID:7148 |
Chronic pain | indication | 82423001 | |
Osteoarthritis | indication | 396275006 | |
Arthritis | off-label use | 3723001 | DOID:848 |
Vascular headache | off-label use | 128187005 | |
Peptic ulcer | contraindication | 13200003 | DOID:750 |
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Gastrointestinal ulcer | contraindication | 40845000 | |
Chronic heart failure | contraindication | 48447003 | |
Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
Gastrointestinal hemorrhage | contraindication | 74474003 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Coronary artery bypass graft | contraindication | 232717009 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Pregnancy, function | contraindication | 289908002 | |
Cardiovascular event risk | contraindication | 395112001 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Smokes tobacco daily | contraindication | 449868002 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 2.81 | acidic |
pKa2 | 12.64 | acidic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Prostaglandin G/H synthase 2 | Enzyme | INHIBITOR | IC50 | 5.09 | WOMBAT-PK | CHEMBL | |||
Prostaglandin G/H synthase 1 | Enzyme | INHIBITOR | IC50 | 4.40 | WOMBAT-PK | CHEMBL | |||
Carbonic anhydrase 2 | Enzyme | Ki | 5.03 | CHEMBL | |||||
Transthyretin | Secreted | Kd1 | 7.13 | WOMBAT-PK | |||||
Carbonic anhydrase 1 | Enzyme | Ki | 5.07 | CHEMBL | |||||
Dihydrofolate reductase | Enzyme | INHIBITOR | Ki | 4.47 | IUPHAR | ||||
2-amino-3-carboxymuconate-6-semialdehyde decarboxylase | Unclassified | Ki | 5.59 | CHEMBL |
ID | Source |
---|---|
4017950 | VUID |
N0000146300 | NUI |
D00130 | KEGG_DRUG |
3393 | RXNORM |
4017950 | VANDF |
C0012228 | UMLSCUI |
CHEBI:39669 | CHEBI |
1FL | PDB_CHEM_ID |
CHEMBL898 | ChEMBL_ID |
DB00861 | DRUGBANK_ID |
D004061 | MESH_DESCRIPTOR_UI |
3059 | PUBCHEM_CID |
7162 | IUPHAR_LIGAND_ID |
3774 | INN_ID |
7C546U4DEN | UNII |
1247 | MMSL |
4595 | MMSL |
d00208 | MMSL |
001599 | NDDF |
20865003 | SNOMEDCT_US |
387116004 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Diflunisal | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-0755 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 25 sections |
Diflunisal | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-0755 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 25 sections |
Diflunisal | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-9222 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 25 sections |
Diflunisal | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-9222 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 25 sections |
diflunisal | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14539-673 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 21 sections |
DIFLUNISAL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52959-379 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 13 sections |
Diflunisal | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-3049 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 14 sections |
Diflunisal | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62135-456 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 21 sections |
DIFLUNISAL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64980-181 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 25 sections |
Diflunisal | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-0848 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 27 sections |
Diflunisal | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68382-530 | TABLET | 500 mg | ORAL | ANDA | 15 sections |
Diflunisal | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70771-1083 | TABLET | 500 mg | ORAL | ANDA | 17 sections |
Diflunisal | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70771-1083 | TABLET | 500 mg | ORAL | ANDA | 17 sections |